Collectively, targeting Treg-specific gp96 not only prevents Treg infiltration into the TME but also hampers their activation due to suboptimal IL-2/p-STAT5 signaling, contributing to heightened antitumor immunity and superior tumor control. This evidence concerns the gene IL2 and neoplasm.